Health Care • Biotechnology: Pharmaceutical Preparations
$48.68 ▼ -0.06
(-0.12%)
MKT CAP: $98.47B • VOL: 5.61M
52W L $46 52W H $62
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$41
MEDIAN
$55
MEAN
$56
HIGH
$66
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE GSK TAPE
GSK // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $58.90 | $55.98 | 2025-02-14 | $44.30 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $61.34 | $57.44 | 2025-02-06 | $45.76 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $55.50 | $53.55 | 2025-01-29 | $46.73 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $49.65 | — | 2025-01-17 | $47.71 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $42.84 | $46.25 | 2025-01-09 | $43.33 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $57.93 | $50.63 | 2024-12-18 | $42.35 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $47.22 | $49.17 | 2024-12-04 | $45.27 | -4.3% | 48% | C |